K
Krzysztof Mrózek
Researcher at Ohio State University
Publications - 225
Citations - 20740
Krzysztof Mrózek is an academic researcher from Ohio State University. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 69, co-authored 209 publications receiving 18895 citations. Previous affiliations of Krzysztof Mrózek include Roswell Park Cancer Institute.
Papers
More filters
Journal ArticleDOI
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
John C. Byrd,Krzysztof Mrózek,Richard K. Dodge,Andrew J. Carroll,Colin G. Edwards,Diane C. Arthur,Mark J. Pettenati,Shivanand R. Patil,Kathleen W. Rao,Michael S. Watson,Prasad Koduru,Joseph O. Moore,Richard Stone,Robert J. Mayer,Eric J. Feldman,Frederick R. Davey,Charles A. Schiffer,Richard A. Larson,Clara D. Bloomfield +18 more
TL;DR: In this paper, the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-to-5-year overall survival (OS) of acute myeloid leukemia (AML) patients was investigated.
Journal ArticleDOI
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Kathryn G. Roberts,Yongjin Li,Debbie Payne-Turner,Richard C. Harvey,Yung-Li Yang,Dehua Pei,Kelly McCastlain,Li Ding,Li Ding,Changxue Lu,Changxue Lu,Guangchun Song,Jing Ma,Jared Becksfort,Michael Rusch,S. C. Chen,John Easton,J. Cheng,Kristy Boggs,Natalia Santiago-Morales,Ilaria Iacobucci,Robert S. Fulton,Robert S. Fulton,Ji Wen,Marcus B. Valentine,Cheng Cheng,Steven W. Paugh,Meenakshi Devidas,Meenakshi Devidas,I-Ming Chen,S. Reshmi,S. Reshmi,Amy Smith,Erin Hedlund,Pankaj Gupta,Panduka Nagahawatte,Gang Wu,Xiang Chen,Donald Yergeau,Bhavin Vadodaria,Heather L. Mulder,Naomi J. Winick,Eric Larsen,William L. Carroll,William L. Carroll,Nyla A. Heerema,Andrew J. Carroll,G. Grayson,Sarah K. Tasian,Andrew S. Moore,F. Keller,Melissa Frei-Jones,J. A. Whitlock,Elizabeth A. Raetz,Deborah L. White,Timothy P. Hughes,J. M. Guidry Auvil,Malcolm A. Smith,Malcolm A. Smith,Guido Marcucci,Clara D. Bloomfield,Krzysztof Mrózek,Jessica Kohlschmidt,Jessica Kohlschmidt,Wendy Stock,Steven M. Kornblau,Marina Konopleva,Elisabeth Paietta,Ching-Hon Pui,Sima Jeha,Mary V. Relling,William E. Evans,Daniela S. Gerhard,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Elaine R. Mardis,Richard K. Wilson,Mignon L. Loh,Mignon L. Loh,James R. Downing,James R. Downing,Stephen P. Hunger,Stephen P. Hunger,Cheryl L. Willman,Cheryl L. Willman,Jinghui Zhang,Charles G. Mullighan,Charles G. Mullighan +87 more
TL;DR: Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors.
Journal ArticleDOI
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci,Kati Maharry,Yue-Zhong Wu,Michael D. Radmacher,Krzysztof Mrózek,Dean Margeson,Kelsi B. Holland,Susan P. Whitman,Heiko Becker,Sebastian Schwind,Klaus H. Metzeler,Bayard L. Powell,Thomas H. Carter,Jonathan E. Kolitz,Meir Wetzler,Andrew J. Carroll,Maria R. Baer,Michael A. Caligiuri,Richard A. Larson,Clara D. Bloomfield +19 more
TL;DR: The R172 IDH2 mutations, previously unreported in AML, characterize a novel subset of CN-AML patients lacking other prognostic mutations and associate with unique gene- and microRNA-expression profiles that may lead to the discovery of novel, therapeutically targetable leukemogenic mechanisms.
Journal Article
Absence of the Wild-Type Allele Predicts Poor Prognosis in Adult de Novo Acute Myeloid Leukemia with Normal Cytogenetics and the Internal Tandem Duplication of FLT3 A Cancer and Leukemia Group B Study
Susan P. Whitman,Kellie J. Archer,Lan Feng,Claudia D. Baldus,Brian Becknell,Brian D. Carlson,Andrew J. Carroll,Krzysztof Mrózek,James W. Vardiman,Stephen L. George,Jonathan E. Kolitz,Richard A. Larson,Clara D. Bloomfield,Michael A. Caligiuri +13 more
TL;DR: A poor prognosis of the relatively young FLT3(ITD/-) adults (median age, 37 years), despite treatment with current dose-intensive regimens, suggests that new treatment modalities, such as therapy with aFLT3 tyrosine kinase inhibitor, are clearly needed for this group of patients.
Journal ArticleDOI
Cytogenetics in acute leukemia
TL;DR: Current views on clinical relevance of major cytogenetic findings in adult AML and ALL are summarized.